Free Trial
NASDAQ:IMVT

Immunovant Q1 2025 Earnings Report

Immunovant logo
$14.46 -0.10 (-0.69%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$14.47 +0.01 (+0.07%)
As of 05/23/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.07
One Year Ago EPS
-$0.57

Immunovant Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunovant Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Immunovant's Q4 2025 earnings is scheduled for Wednesday, June 4, 2025, with a conference call scheduled on Friday, May 30, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Immunovant Earnings Headlines

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) PT at $38.33
Little-known 2021 NYSE “loophole” for Bitcoin enthusiasts
We’re on the edge of what could be a massive parabolic move in Bitcoin that pushes the price past all-time highs… and over $100K. There was a little-known move by the NYSE in late 2021 that opened up a “loophole” for anyone with a regular brokerage account to take advantage of Bitcoin. Combined with a Trump presidency—who says he wants to be known as the first “Crypto President”—this creates an unprecedented opportunity.
Immunovant downgraded to Neutral from Buy at UBS
See More Immunovant Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email.

About Immunovant

Immunovant (NASDAQ:IMVT), a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

View Immunovant Profile

More Earnings Resources from MarketBeat